HOME >> BIOLOGY >> NEWS
Second Gene Responsible For Tuberous Sclerosis Complex Identified

TSC1 Finding on Chromosome 9 Follows 1993 Discovery of TSC2 Gene

Scientists have identified the second of two genes that cause tuberous sclerosis complex (TSC), a relatively common developmental disorder characterized by a number of abnormalities, including seizures, benign tumors in several organs, and variable emotional and cognitive disabilities. The discovery, to be reported in the August 8, 1997, issue of Science* by David Kwiatkowski, M.D., Ph.D., and colleagues at Brigham and Women's Hospital in Boston, was funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Human Genome Research Institute (NHGRI), both components of the National Institutes of Health.

Investigators located the TSC1 gene on chromosome 9. The gene makes a protein called hamartin, named after hamartomas, a type of tumor common to TSC and comprised of multiple cell types. Affected individuals have a mutation in either the TSC1 gene or the TSC2 gene. The TSC2 gene, which codes for a protein called tuberin, is located on chromosome 16 and was identified in 1993 by a European consortium of investigators. Both the TSC1 and TSC2 genes are thought to function as tumor suppressor genes and join more than a dozen other such genes that play an important role in the control of cell growth. In their normal form, tumor suppressor genes keep cells from multiplying unchecked in the body and prevent tumor development.

TSC occurs in one in 6,000 live births and affects a total of 40,000 Americans and 1,000,000 people worldwide. It is called a complex because of the wide range of clinical manifestations. Clinical signs may be subtle and, as a result, TSC can go unrecognized or misdiagnosed for many years. Although in some individuals it may take considerable time before symptoms develop, TSC is known primarily as a childhood disorder. Generally speaking, the clinical manifestations of TSC are the same for both genes. Seizures are the most co
'"/>

Contact: Stephanie Clipper
smtp:clippers@ninds.nih.gov
301/496-5751
NIH/National Institute of Neurological Disorders and Stroke
8-Aug-1997


Page: 1 2 3 4

Related biology news :

1. Second call for proposals for the European Young Investigator Award
2. Second generation targeted antibodies - Its all in the binding
3. Secondary complications and restoration of function in SCI
4. Second EMBO International Practical Workshop for Science Teachers
5. NTP-CERHR announces the Second Phthalates Expert Panel Meeting to be held December 15-17, 1999
6. In Logged Forests, Hunting of Wildlife Becomes Deadly Second Harvest
7. Iron Supplemented Formula Milk Should Be Free For Inner City Children Into Their Second Year Of Life
8. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
9. When One Gene Has Two Roles, Its Second Function May Be Missed
10. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
11. The Second Visible Human Project Conference

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/19/2020)... (PRWEB) , ... March 17, 2020 , ... ... tools for characterizing microbiome populations down to the strain level, recently unveiled a ... Shoreline Wave amplicon kit contains the same innovative amplification capabilities as the Shoreline ...
(Date:3/11/2020)... ... March 11, 2020 , ... ... company backed by Siemens Healthineers and several healthcare VC firms introduces a first ... people in over 100 countries and has caused over 4,000 fatalities to date. ...
(Date:3/5/2020)... ... March 05, 2020 , ... Cytonus ... comprised of the industry’s key opinion leaders and distinguished research scientists, collectively ... Cytonus is a leading cell-based platform technology company focused on the development ...
Breaking Biology News(10 mins):
(Date:2/21/2020)... ... , ... In a free session on Tuesday, March 10, 2020 ... Dilworth, BS, MS, Vice President Rare, Orphan and Pediatric Diseases, and Rachael Young, Associate ... support patients, sites and sponsors. , When planning a rare disease clinical trial, drug ...
(Date:2/19/2020)... FARMINGTON, Conn. (PRWEB) , ... February 18, 2020 ... ... that develops tools for characterizing microbiome populations down to the strain level, recently ... and easy-to-use kit designed for efficient and unbiased isolation of high molecular weight ...
(Date:2/11/2020)... ... 11, 2020 , ... Synagro Technologies, Inc. , the ... that the City of Fort Worth has partnered with Synagro of Texas-CDR (Synagro) ... of 2020, Synagro will assume operation of the city’s current biosolids management facility ...
(Date:2/3/2020)... and CAMBRIDGE, Mass. (PRWEB) , ... February 03, ... ... Budapest with US offices in Cambridge, MA, announce that OmniType, the 11-locus, single ... (EAP) from today. OmniType is a best-in-class product featuring locus-multiplexing and short library ...
Breaking Biology Technology:
Cached News: